CR20200418A - Inhibidores de orginasa y sus mètodos de uso antecedentes - Google Patents

Inhibidores de orginasa y sus mètodos de uso antecedentes

Info

Publication number
CR20200418A
CR20200418A CR20200418A CR20200418A CR20200418A CR 20200418 A CR20200418 A CR 20200418A CR 20200418 A CR20200418 A CR 20200418A CR 20200418 A CR20200418 A CR 20200418A CR 20200418 A CR20200418 A CR 20200418A
Authority
CR
Costa Rica
Prior art keywords
sup
sub
methods
nhr
compounds
Prior art date
Application number
CR20200418A
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Steve Cook
Dedong Wu
Iain Simpson
Maurice Raymond Verschoyle Finlay
Jianyan Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20200418A publication Critical patent/CR20200418A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Se divulgan compuestos de fórmula (Ia) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ia) y métodos para utilizarlas en el tratamiento del cáncer o una enfermedad respiratoria inflamatoria y la inhibición de la arginasa:donde<br /> R1 es -NHR1a; R1a es -H o -C(O)CH(R1b)NHR1c; y R1b se selecciona entre -H, -alquilo (C1-C4) y CH2OR1d y R1c es -H; o R1b y R1c, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1d es H o –CH3.</p>
CR20200418A 2018-02-17 2019-02-15 Inhibidores de orginasa y sus mètodos de uso antecedentes CR20200418A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20200418A true CR20200418A (es) 2020-10-27

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200418A CR20200418A (es) 2018-02-17 2019-02-15 Inhibidores de orginasa y sus mètodos de uso antecedentes

Country Status (34)

Country Link
US (4) US11420984B2 (es)
EP (2) EP4678238A2 (es)
JP (2) JP7317841B2 (es)
KR (1) KR102657919B1 (es)
CN (3) CN117186134A (es)
AU (2) AU2019221896B2 (es)
BR (1) BR112020015973A2 (es)
CA (1) CA3091365A1 (es)
CL (1) CL2020002096A1 (es)
CR (1) CR20200418A (es)
DK (1) DK3752251T3 (es)
DO (1) DOP2020000145A (es)
EC (1) ECSP20058183A (es)
ES (1) ES3058584T3 (es)
FI (1) FI3752251T3 (es)
HR (1) HRP20251592T1 (es)
IL (1) IL276711B2 (es)
JO (1) JOP20200197A1 (es)
LT (1) LT3752251T (es)
MA (1) MA51837B1 (es)
MX (1) MX2020008570A (es)
NI (1) NI202000055A (es)
PE (1) PE20210176A1 (es)
PL (1) PL3752251T4 (es)
PT (1) PT3752251T (es)
RS (1) RS67559B1 (es)
SG (1) SG11202007739XA (es)
SI (1) SI3752251T1 (es)
SM (1) SMT202500499T1 (es)
TW (1) TWI803574B (es)
UA (1) UA129083C2 (es)
UY (1) UY38096A (es)
WO (1) WO2019159120A1 (es)
ZA (2) ZA202305542B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
KR102668252B1 (ko) 2018-08-22 2024-05-21 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12021551902A1 (en) * 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN114599372A (zh) * 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CN119213001A (zh) * 2022-06-08 2024-12-27 株式会社大熊制药 精氨酸酶抑制剂和包含其的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027034B1 (pt) * 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
IN2014DN09678A (es) 2012-04-18 2015-07-31 Mars Inc
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US11655260B2 (en) 2017-12-22 2023-05-23 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PH12021551902A1 (en) * 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
HRP20251592T1 (hr) 2026-02-13
ES3058584T3 (en) 2026-03-11
ZA202407941B (en) 2025-06-25
PL3752251T3 (pl) 2026-02-16
WO2019159120A1 (en) 2019-08-22
IL276711A (en) 2020-09-30
UY38096A (es) 2019-07-31
PL3752251T4 (pl) 2026-02-16
ECSP20058183A (es) 2020-10-30
EP4678238A2 (en) 2026-01-14
DK3752251T3 (da) 2025-12-15
IL276711B2 (en) 2024-06-01
UA129083C2 (uk) 2025-01-08
CN111712302A (zh) 2020-09-25
US12195485B2 (en) 2025-01-14
KR20200122341A (ko) 2020-10-27
US20230365599A1 (en) 2023-11-16
NZ767738A (en) 2023-12-22
AU2019221896B2 (en) 2022-03-24
MA51837B1 (fr) 2025-12-31
SMT202500499T1 (it) 2026-01-12
CA3091365A1 (en) 2019-08-22
AU2022203938A1 (en) 2022-06-23
JOP20200197A1 (ar) 2020-08-16
AU2022203938B2 (en) 2024-02-01
US11420984B2 (en) 2022-08-23
RS67559B1 (sr) 2026-01-30
IL276711B1 (en) 2024-02-01
US20210002305A1 (en) 2021-01-07
NI202000055A (es) 2021-06-22
FI3752251T3 (fi) 2025-12-12
TW201945004A (zh) 2019-12-01
SI3752251T1 (sl) 2026-02-27
CN111712302B (zh) 2023-09-19
CL2020002096A1 (es) 2020-12-18
ZA202305542B (en) 2025-03-26
LT3752251T (lt) 2026-01-12
AU2019221896A1 (en) 2020-10-01
JP2023145557A (ja) 2023-10-11
EP3752251A1 (en) 2020-12-23
PE20210176A1 (es) 2021-01-29
TWI803574B (zh) 2023-06-01
BR112020015973A2 (pt) 2020-12-15
CN117186134A (zh) 2023-12-08
MA51837A (fr) 2021-06-16
EP3752251B1 (en) 2025-09-10
KR102657919B1 (ko) 2024-04-15
US20230122859A1 (en) 2023-04-20
US11912727B2 (en) 2024-02-27
PT3752251T (pt) 2026-01-13
JP2021513964A (ja) 2021-06-03
SG11202007739XA (en) 2020-09-29
MX2020008570A (es) 2020-09-21
DOP2020000145A (es) 2020-09-15
JP7699171B2 (ja) 2025-06-26
CN117180290A (zh) 2023-12-08
US20250313578A1 (en) 2025-10-09
JP7317841B2 (ja) 2023-07-31

Similar Documents

Publication Publication Date Title
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
JOP20200197A1 (ar) مثبطات أرجيناز وطرق لاستخدامها
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
RU2019142472A (ru) Глюкуронидные пролекарства ингибиторов янус-киназы
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
GEAP202215588A (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
RU2013136895A (ru) Новое бициклическое соединение или его соль
DOP2024000181A (es) Inhibidores de arginasa y métodos de uso de estos
EA200701780A1 (ru) Противоопухолевое средство
WO2009009531A3 (en) Pyrimidinecarboxamide derivatives for the treatment of hiv infections
PH12022551429A1 (en) Compound and composition as pdgf receptor kinase inhibitor
MX392452B (es) Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
CY1112596T1 (el) Νεες ενωσεις και χρηση αυτων
EA202091886A1 (ru) Ингибиторы аргиназы и способы их применения
TH2001004359A (th) ตัวยับยั้งอาร์จิเนสและวิธีการใช้สิ่งดังกล่าว
RU2015151257A (ru) Фармацевтическое применение соединения гексагидродибензо[a, g]хинолизина